Molecular Evolution and Increasing Macrolide Resistance of Bordetella pertussis, Shanghai, China, 2016-2022

Emerg Infect Dis. 2023 Jan;30(1):29-38. doi: 10.3201/eid3001.221588.

Abstract

Resurgence and spread of macrolide-resistant Bordetella pertussis (MRBP) threaten global public health. We collected 283 B. pertussis isolates during 2016-2022 in Shanghai, China, and conducted 23S rRNA gene A2047G mutation detection, multilocus variable-number tandem-repeat analysis, and virulence genotyping analysis. We performed whole-genome sequencing on representative strains. We detected pertussis primarily in infants (0-1 years of age) before 2020 and older children (>5-10 years of age) after 2020. The major genotypes were ptxP1/prn1/fhaB3/ptxA1/ptxC1/fim2-1/fim3-1 (48.7%) and ptxP3/prn2/fhaB1/ptxA1/ptxC2/fim2-1/fim3-1 (47.7%). MRBP increased remarkably from 2016 (36.4%) to 2022 (97.2%). All MRBPs before 2020 harbored ptxP1, and 51.4% belonged to multilocus variable-number tandem-repeat analysis type (MT) 195, whereas ptxP3-MRBP increased from 0% before 2020 to 66.7% after 2020, and all belonged to MT28. MT28 ptxP3-MRBP emerged only after 2020 and replaced the resident MT195 ptxP1-MRBP, revealing that 2020 was a watershed in the transformation of MRBP.

Keywords: Bordetella pertussis; China; Shanghai; antimicrobial resistance; bacteria; genotype; macrolide; vaccine-preventable diseases.

MeSH terms

  • Adolescent
  • Anti-Bacterial Agents / pharmacology
  • Bordetella pertussis* / genetics
  • Child
  • Child, Preschool
  • China / epidemiology
  • Drug Resistance, Bacterial / genetics
  • Evolution, Molecular
  • Humans
  • Infant
  • Macrolides / pharmacology
  • Whooping Cough* / epidemiology

Substances

  • Anti-Bacterial Agents
  • Macrolides